Table 3.
Crude and adjusted associations of postoperative oral morphine equivalent amounts (in mg) and risk of revision by 1 year and 5 years
| 1-year revision |
5-year revision |
|||||
|---|---|---|---|---|---|---|
| Time period OMEs (mg range)a | Crude HR (95% CI) | Adjusted HR (95% CI) | p-value | Crude HR (95% CI) | Adjusted HR (95% CI) | p-value |
| Days 1–90b | ||||||
| 1st quartile: < 135 | 0.9 (0.5–2.0) | 1.0 (0.5–2.0) | 0.9 | 0.7 (0.4–1.4) | 0.7 (0.4–1.3) | 0.3 |
| 2nd quartile: 135–209 | 0.7 (0.3–1.4) | 0.7 (0.4–1.4) | 0.3 | 0.8 (0.4–1.4) | 0.8 (0.4–1.4) | 0.4 |
| 3rd quartile: 210–429 | 1.3 (0.7–2.6) | 1.4 (0.7–2.7) | 0.3 | 1.2 (0.7–2.1) | 1.1 (0.6–2.0) | 0.7 |
| 4th quartile: ≥ 430 | 1.6 (0.9–3.0) | 1.7 (0.9–3.2) | 0.01 | 1.7 (1.0–3.0) | 1.5 (0.8–2.7) | 0.2 |
| Days 91–360c | ||||||
| 1st quartile: < 90 | 2.4 (0.3–23) | 2.6 (0.3–25) | 0.4 | 1.8 (0.8–3.7) | 1.8 (0.9–3.7) | 0.1 |
| 2nd quartile: 90–269 | 17 (4.6–64) | 20 (5.4–76) | < 0.001 | 3.0 (1.7–5.3) | 3.0 (1.7–5.2) | < 0.001 |
| 3rd quartile: 270–872 | 38 (11–130) | 54 (15–190) | < 0.001 | 4.6 (2.7–7.8) | 4.3 (2.5–7.4) | < 0.001 |
| 4th quartile: ≥ 873 | 16 (3.9–63) | 43 (12–157) | < 0.001 | 3.8 (2.2–6.5) | 3.2 (1.7–6.1) | < 0.001 |
| Days 91–180c | ||||||
| 1st quartile: < 100 | 1.4 (0.3–6.1) | 1.5 (0.4–6.6) | 0.6 | 2.0 (1.1–3.5) | 2.0 (1.1–3.5) | 0.02 |
| 2nd quartile: 100–219 | 5.2 (2.2t–12) | 6.2 (2.6–15) | < 0.001 | 2.7 (1.6–4.7) | 2.7 (1.6–4.6) | < 0.001 |
| 3rd quartile: 220–533 | 3.5 (1.2–11) | 4.9 (1.8–13) | 0.002 | 2.1 (1.1–3.9) | 2.0 (1.0–3.7) | 0.05 |
| 4th quartile: ≥ 534 | 4.9 (2.0–12) | 11 (2.9–44) | 0.001 | 4.0 (2.4–6.6) | 3.6 (2.1–6.1) | < 0.001 |
| Days 181–270b,d | ||||||
| 1st quartile: < 90 | 1.6 (0.2–13) | 1.8 (0.23–14) | 0.6 | 2.1 (1.0–4.6) | 2.2 (1.0–4.7) | 0.05 |
| 2nd quartile: 90–214 | 12 (4.8–32) | 17 (6.2–44) | < 0.001 | 2.6 (1.4–4.8) | 2.6 (1.4–4.8) | 0.002 |
| 3rd quartile: 215559 | 8.0 (2.6–24) | 14 (4.2–46) | < 0.001 | 2.7 (1.4–5.0) | 2.5 (1.3–4.9) | 0.005 |
| 4th quartile: ≥ 560 | – | – | – | 2.7 (1.4–5.0) | 2.4 (1.3–4.6) | 0.006 |
| Days 270–360d,e | ||||||
| 1st quartile: < 85 | – | – | – | 2.1 (1.1–4.3) | 2.1 (1.1–4.3) | 0.04 |
| 2nd quartile: 85–209 | – | – | – | 1.2 (0.5–2.9) | 1.1 (0.5–2.7) | 0.8 |
| 3rd quartile: 210–579 | – | – | – | 3.4 (1.9–6.1) | 3.1 (1.7–5.5) | < 0.001 |
| 4th quartile: ≥ 580 | – | – | – | 3.0 (1.6–5.7) | 1.9 (0.9–4.4) | 0.1 |
a
Reference = no opioid.
b
1- and 5-year revision models adjusted for age and gender.
c
- and 5-year revision models adjusted for age, gender, and previous opioid use.
d
Due to insufficient events, risk estimates for days 181–270 for the 4th quartile and for the entire period of days 271–360 could not be provided.
e
5-year model adjusted for age and gender.